186 related articles for article (PubMed ID: 34514091)
1. Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development.
Ho TY; Mealiea D; Okamoto L; Stojdl DF; McCart JA
Mol Ther Oncolytics; 2021 Sep; 22():85-97. PubMed ID: 34514091
[TBL] [Abstract][Full Text] [Related]
2. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
Zeh HJ; Downs-Canner S; McCart JA; Guo ZS; Rao UN; Ramalingam L; Thorne SH; Jones HL; Kalinski P; Wieckowski E; O'Malley ME; Daneshmand M; Hu K; Bell JC; Hwang TH; Moon A; Breitbach CJ; Kirn DH; Bartlett DL
Mol Ther; 2015 Jan; 23(1):202-14. PubMed ID: 25292189
[TBL] [Abstract][Full Text] [Related]
3. Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function.
Nakatake M; Kurosaki H; Kuwano N; Horita K; Ito M; Kono H; Okamura T; Hasegawa K; Yasutomi Y; Nakamura T
Mol Ther Oncolytics; 2019 Sep; 14():159-171. PubMed ID: 31236440
[TBL] [Abstract][Full Text] [Related]
4. Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells.
Cao F; Nguyen P; Hong B; DeRenzo C; Rainusso NC; Rodriguez Cruz T; Wu MF; Liu H; Song XT; Suzuki M; Wang LL; Yustein JT; Gottschalk S
Adv Cell Gene Ther; 2021 Apr; 4(2):. PubMed ID: 33829146
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy.
Shakiba Y; Vorobyev PO; Mahmoud M; Hamad A; Kochetkov DV; Yusubalieva GM; Baklaushev VP; Chumakov PM; Lipatova AV
Biochemistry (Mosc); 2023 Jun; 88(6):823-841. PubMed ID: 37748878
[TBL] [Abstract][Full Text] [Related]
6. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
8. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
9. Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase.
Islam SMBU; Lee B; Jiang F; Kim EK; Ahn SC; Hwang TH
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963415
[TBL] [Abstract][Full Text] [Related]
10. Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.
Hughes J; Wang P; Alusi G; Shi H; Chu Y; Wang J; Bhakta V; McNeish I; McCart A; Lemoine NR; Wang Y
Gene Ther; 2015 Jun; 22(6):476-84. PubMed ID: 25876464
[TBL] [Abstract][Full Text] [Related]
11. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
12. Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase.
Islam SMBU; Hong YM; Ornella MSC; Ngabire D; Jang H; Cho E; Kim EK; Hale JJJ; Kim CH; Ahn SC; Cho M; Hwang TH
Biomedicines; 2020 Oct; 8(10):. PubMed ID: 33081279
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.
John LB; Howland LJ; Flynn JK; West AC; Devaud C; Duong CP; Stewart TJ; Westwood JA; Guo ZS; Bartlett DL; Smyth MJ; Kershaw MH; Darcy PK
Cancer Res; 2012 Apr; 72(7):1651-60. PubMed ID: 22315352
[TBL] [Abstract][Full Text] [Related]
14. Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity.
Hirvinen M; Capasso C; Guse K; Garofalo M; Vitale A; Ahonen M; Kuryk L; Vähä-Koskela M; Hemminki A; Fortino V; Greco D; Cerullo V
Mol Ther Oncolytics; 2016; 3():16002. PubMed ID: 27626058
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
Fend L; Remy-Ziller C; Foloppe J; Kempf J; Cochin S; Barraud L; Accart N; Erbs P; Fournel S; Préville X
Oncoimmunology; 2016 Feb; 5(2):e1080414. PubMed ID: 27057460
[TBL] [Abstract][Full Text] [Related]
16. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome Changes in Glioma Cells upon Infection with the Oncolytic Virus VV-GMCSF-Lact.
Semenov DV; Vasileva NS; Dymova MA; Mishinov SV; Savinovskaya YI; Ageenko AB; Dome AS; Zinchenko ND; Stepanov GA; Kochneva GV; Richter VA; Kuligina EV
Cells; 2023 Nov; 12(22):. PubMed ID: 37998351
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer.
Umer BA; Noyce RS; Franczak BC; Shenouda MM; Kelly RG; Favis NA; Desaulniers M; Baldwin TA; Hitt MM; Evans DH
Cancer Immunol Res; 2020 May; 8(5):618-631. PubMed ID: 32127390
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
20. Complementation of a vaccinia virus host-range K1L gene deletion by the nonhomologous CP77 gene.
Ramsey-Ewing AL; Moss B
Virology; 1996 Aug; 222(1):75-86. PubMed ID: 8806489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
